Edition:
United States

Titan Pharmaceuticals Inc (TTNP.OQ)

TTNP.OQ on NASDAQ Stock Exchange Capital Market

1.23USD
15 Dec 2017
Change (% chg)

$-0.03 (-2.00%)
Prev Close
$1.25
Open
$1.25
Day's High
$1.25
Day's Low
$1.20
Volume
23,789
Avg. Vol
30,910
52-wk High
$4.75
52-wk Low
$1.20

Select another date:

Tue, Nov 28 2017

BRIEF-Titan Pharmaceuticals Says Co​ Entered Into A Binding Term Sheet With L. Molteni & C. Dei F.Lli Alitti Societ*I Esercizio

* TITAN PHARMACEUTICALS INC - ON NOV 27, CO​ ENTERED INTO A BINDING TERM SHEET WITH L. MOLTENI & C. DEI F.LLI ALITTI SOCIET*I ESERCIZIO - SEC FILING

BRIEF-Titan Pharmaceuticals Partners With Molteni To Market Probuphine In Europe

* TITAN PHARMACEUTICALS PARTNERS WITH MOLTENI TO MARKET PROBUPHINE® IN EUROPE

CORRECTED-BRIEF-European Medicines Agency Accepts Titan's Marketing Application For Probuphine

* EUROPEAN MEDICINES AGENCY ACCEPTS TITAN PHARMACEUTICALS' MARKETING AUTHORIZATION APPLICATION FOR PROBUPHINE®

BRIEF-Titan Pharmaceuticals reports Q3 loss per share of $0.20

* Titan pharmaceuticals reports third quarter 2017 financial results

BRIEF-Titan Pharmaceuticals files for offering of up to 280,612 shares by selling stockholder

* Titan Pharmaceuticals Inc files for offering of up to 280,612 shares of co's common stock by the selling stockholder - SEC filing‍​ Source text:[http://bit.ly/2izOUEZ] Further company coverage:

BRIEF-Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

* Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

BRIEF-Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse

* Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

BRIEF-Titan Pharma receives FDA clearance to begin clinical study of Parkinson's disease treatment

* Titan Pharmaceuticals receives fda clearance to begin clinical study of Parkinson's disease treatment Source text for Eikon: Further company coverage:

BRIEF-Titan Pharmaceuticals Q2 loss per share $0.16

* Titan Pharmaceuticals reports second quarter 2017 financial results

BRIEF-Titan Pharmaceuticals secures $10 mln debt facility from Horizon Technology Finance

* Titan Pharmaceuticals secures $10 million debt facility from Horizon Technology Finance

Select another date: